Eli Lilly to Invest Over $1 Billion in India to Boost Manufacturing…

Sarah J · 2025-10-06T21:26:14.000Z

Global pharma leader Eli Lilly has announced plans to invest more than $1 billion in India to expand its drug manufacturing and strengthen its global supply chain. The investment will primarily go into partnerships with Indian contract manufacturers to produce high-demand medicines for obesity, diabetes, Alzheimer’s, cancer, and autoimmune diseases . As part of this expansion, Lilly will set up a manufacturing and quality hub in Hyderabad , which will coordinate production with Indian partners and serve as a center of excellence for technical and regulatory capabilities. The company will begin hiring engineers, chemists, and quality specialists immediately to support this growth. Currently, Eli Lilly operates in India through marketing and clinical development but does not own a local manufacturing facility. The new investment marks a strategic shift to leverage India’s growing pharmaceutical manufacturing ecosystem and cost efficiencies. The move aligns with Lilly’s broader global expansion plan, which includes major new plants in the U.S. and Europe, and comes amid surging demand for its blockbuster Mounjaro obesity drug. This expansion positions India as a key player in Lilly’s global operations and underscores the country’s rising importance in the biopharma supply chain.

Member Login Get Access

Eli Lilly to Invest Over $1 Billion in India to Boost Manufacturing… | SEINET